| Year |
Citation |
Score |
| 2024 |
Jiao Y, Yan J, Sutaria DS, Lu P, Vicchiarelli M, Reyna Z, Ruiz-Delgado J, Burk E, Moon E, Shah NR, Spellberg B, Bonomo RA, Drusano GL, Louie A, Luna BM, et al. Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models. Antimicrobial Agents and Chemotherapy. e0139423. PMID 38289076 DOI: 10.1128/aac.01394-23 |
0.32 |
|
| 2023 |
Jacobsson S, Golparian D, Oxelbark J, Kong FYS, Da Costa RMA, Franceschi F, Brown D, Louie A, Drusano G, Unemo M. Pharmacodynamics of zoliflodacin plus doxycycline combination therapy against in a gonococcal hollow-fiber infection model. Frontiers in Pharmacology. 14: 1291885. PMID 38130409 DOI: 10.3389/fphar.2023.1291885 |
0.397 |
|
| 2023 |
Tilanus A, Drusano G. Inoculum-Based Dosing: A Novel Concept for Combining Time with Concentration-Dependent Antibiotics to Optimize Clinical and Microbiological Outcomes in Severe Gram Negative Sepsis. Antibiotics (Basel, Switzerland). 12. PMID 37998783 DOI: 10.3390/antibiotics12111581 |
0.411 |
|
| 2023 |
Tilanus A, Drusano G. Optimizing the Use of Beta-Lactam Antibiotics in Clinical Practice: A Test of Time. Open Forum Infectious Diseases. 10: ofad305. PMID 37416756 DOI: 10.1093/ofid/ofad305 |
0.332 |
|
| 2022 |
Jacobsson S, Golparian D, Oxelbark J, Wicha WW, da Costa RMA, Franceschi F, Brown D, Louie A, Gelone SP, Drusano G, Unemo M. Pharmacodynamic evaluation of lefamulin in the treatment of gonorrhea using a hollow fiber infection model simulating infections. Frontiers in Pharmacology. 13: 1035841. PMID 36452226 DOI: 10.3389/fphar.2022.1035841 |
0.39 |
|
| 2022 |
Jacobsson S, Golparian D, Oxelbark J, Franceschi F, Brown D, Louie A, Drusano G, Unemo M. Pharmacodynamic Evaluation of Zoliflodacin Treatment of Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model. Frontiers in Pharmacology. 13: 874176. PMID 35496288 DOI: 10.3389/fphar.2022.874176 |
0.354 |
|
| 2021 |
Durand-Reville TF, Miller AA, O'Donnell JP, Wu X, Sylvester MA, Guler S, Iyer R, Shapiro AB, Carter NM, Velez-Vega C, Moussa SH, McLeod SM, Chen A, Tanudra AM, Zhang J, ... ... Drusano GL, et al. Rational design of a new antibiotic class for drug-resistant infections. Nature. PMID 34526714 DOI: 10.1038/s41586-021-03899-0 |
0.344 |
|
| 2021 |
Jacobsson S, Golparian D, Oxelbark J, Alirol E, Franceschi F, Gustafsson TN, Brown D, Louie A, Drusano G, Unemo M. Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against in a Dynamic Hollow Fiber Infection Model. Frontiers in Pharmacology. 12: 682135. PMID 34093206 DOI: 10.3389/fphar.2021.682135 |
0.364 |
|
| 2021 |
Drusano GL, Bonomo RA, Marshall SM, Rojas LJ, Adams MD, Mojica MF, Kreiswirth BN, Chen L, Mtchedlidze N, Bacci M, Vicchiarelli M, Bulitta JB, Louie A. Emergence of resistance to ceftazidime-avibactam in a derepressed producing isolate in a Hollow Fiber Infection Model. Antimicrobial Agents and Chemotherapy. PMID 33782013 DOI: 10.1128/AAC.00124-21 |
0.31 |
|
| 2021 |
Lodise TP, Drusano G. Vancomycin Area Under the Curve-Guided Dosing and Monitoring for Adult and Pediatric Patients With Suspected or Documented Serious Methicillin-Resistant Staphylococcus aureus Infections: Putting the Safety of Our Patients First. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 33740042 DOI: 10.1093/cid/ciaa1744 |
0.37 |
|
| 2021 |
Drusano GL, Rogers S, Brown D, Peloquin CA, Neely M, Yamada W, Kim S, Almoslem M, Schmidt S, Louie A. Dose-fractionation of moxifloxacin for the treatment of tuberculosis: impact of dosing interval and elimination half-life on microbial kill and resistance suppression. Antimicrobial Agents and Chemotherapy. PMID 33468465 DOI: 10.1128/AAC.02533-20 |
0.384 |
|
| 2020 |
Drusano GL, Duncanson B, Scanga CA, Kim S, Schmidt S, Neely MN, Yamada WM, Vicchiarelli M, Peloquin CA, Louie A. Developing new drugs for the therapy of : What information do we get from pre-clinical animal models? Antimicrobial Agents and Chemotherapy. PMID 32958720 DOI: 10.1128/Aac.01376-20 |
0.433 |
|
| 2020 |
Drusano GL, Neely MN, Kim S, Yamada WM, Schmidt S, Duncanson B, Nole J, Mtchedlidze N, Peloquin CA, Louie A. Building optimal 3-drug combination chemotherapy regimens. Antimicrobial Agents and Chemotherapy. PMID 32900682 DOI: 10.1128/Aac.01610-20 |
0.406 |
|
| 2020 |
Theuretzbacher U, Barbee L, Connolly K, Drusano G, Fernandes P, Hook E, Jerse A, O'Donnell J, Unemo M, Van Bambeke F, VanScoy B, Warn P, Werth BJ, Franceschi F, Alirol E. Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea - challenges and opportunities. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. PMID 32798687 DOI: 10.1016/J.Cmi.2020.08.006 |
0.376 |
|
| 2020 |
Seña AC, Bachmann L, Johnston C, Wi T, Workowski K, Hook EW, Hocking JS, Drusano G, Unemo M. Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction. The Lancet. Infectious Diseases. PMID 32569625 DOI: 10.1016/S1473-3099(20)30171-7 |
0.401 |
|
| 2020 |
Kim S, Scanga CA, Miranda Silva C, Zimmerman M, Causgrove C, Stein B, Dartois V, Peloquin CA, Graham E, Louie A, Flynn JL, Schmidt S, Drusano GL. Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. 105421. PMID 32531349 DOI: 10.1016/J.Ejps.2020.105421 |
0.349 |
|
| 2020 |
Johnson A, McEntee L, Farrington N, Kolamunnage-Dona R, Franzoni S, Vezzelli A, Massimiliano M, Knechtle P, Belley A, Dane A, Drusano G, Das S, Hope W. Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum Beta Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia caused by ESBL-Producing . Antimicrobial Agents and Chemotherapy. PMID 32253209 DOI: 10.1128/Aac.00180-20 |
0.42 |
|
| 2020 |
Kim TH, Tao X, Moya B, Jiao Y, Basso KB, Zhou J, Lang Y, Sutaria DS, Zavascki AP, Barth AL, Reeve SM, Schweizer HP, Deveson Lucas D, Boyce JD, Bonomo RA, ... ... Drusano GL, et al. Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant and . Mbio. 11. PMID 32047131 DOI: 10.1128/Mbio.03189-19 |
0.362 |
|
| 2019 |
Pogue JM, Jones RN, Bradley JS, Andes DR, Bhavnani SM, Drusano GL, Dudley MN, Flamm RK, Rodvold KA, Ambrose PG. Polymyxin susceptibility testing and interpretive breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). Antimicrobial Agents and Chemotherapy. PMID 31767718 DOI: 10.1128/Aac.01495-19 |
0.417 |
|
| 2019 |
Foerster S, Drusano G, Golparian D, Neely M, Piddock LJV, Alirol E, Unemo M. In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae. The Journal of Antimicrobial Chemotherapy. 74: 3521-3529. PMID 31730160 DOI: 10.1093/Jac/Dkz376 |
0.418 |
|
| 2019 |
Kaye KS, Patel T, Drusano G. Is Daptomycin plus Ceftaroline the Way To Go for Methicillin-Resistant Staphylococcus aureus Bacteremia? Antimicrobial Agents and Chemotherapy. 63. PMID 31640979 DOI: 10.1128/Aac.01725-19 |
0.411 |
|
| 2019 |
Shearer JD, Saylor ML, Butler CM, Treston AM, Heine HS, Chirakul S, Schweizer HP, Louie A, Drusano GL, Zumbrun SD, Warfield KL. GC-072: A Novel Therapeutic Candidate for Oral Treatment of Melioidosis and Infections Caused by Select Biothreat Pathogens. Antimicrobial Agents and Chemotherapy. PMID 31548183 DOI: 10.1128/Aac.00834-19 |
0.439 |
|
| 2019 |
Hook EW, Newman L, Drusano G, Evans S, Handsfield HH, Jerse AE, Kong FYS, Lee JY, Taylor SN, Deal C. Development of New Antimicrobials for Urogenital Gonorrhea Therapy: Clinical Trial Design Considerations. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 31538646 DOI: 10.1093/Cid/Ciz899 |
0.379 |
|
| 2019 |
Luna BM, Yan J, Reyna Z, Moon E, Nielsen TB, Reza H, Lu P, Bonomo R, Louie A, Drusano G, Bulitta J, She R, Spellberg B. Natural history of Acinetobacter baumannii infection in mice. Plos One. 14: e0219824. PMID 31318907 DOI: 10.1371/Journal.Pone.0219824 |
0.358 |
|
| 2019 |
Ohata Y, Tomita Y, Sunakawa K, Drusano GL, Tanigawara Y. Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis. International Journal of Antimicrobial Agents. PMID 31279154 DOI: 10.1016/J.Ijantimicag.2019.06.021 |
0.309 |
|
| 2019 |
Drusano GL, Shields RK, Mtchedlidze N, Nguyen MH, Clancy CJ, Vicciarelli M, Louie A. Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2 Bearing Isolates of in a Hollow Fiber Infection Model. Antimicrobial Agents and Chemotherapy. PMID 31160285 DOI: 10.1128/Aac.00462-19 |
0.454 |
|
| 2019 |
Papp-Wallace KM, Zeiser ET, Becka SA, Park S, Wilson BM, Winkler ML, D'Souza R, Singh I, Sutton G, Fouts DE, Chen L, Kreiswirth BN, Ellis-Grosse EJ, Drusano GL, Perlin DS, et al. Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa. The Journal of Infectious Diseases. PMID 31099835 DOI: 10.1093/Infdis/Jiz149 |
0.453 |
|
| 2019 |
Jiao Y, Moya B, Chen MJ, Zavascki AP, Tsai H, Tao X, Sutaria DS, Louie A, Boyce JD, Lucas DD, Kim TH, Tsuji BT, Bonomo RA, Drusano GL, Bulitta JB. Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β-Lactam plus Aminoglycoside in Gram-negatives: A Meta-analysis of Randomized, Controlled Trials. Antimicrobial Agents and Chemotherapy. PMID 30988147 DOI: 10.1128/Aac.00425-19 |
0.311 |
|
| 2019 |
Bulitta JB, Hope W, Eakin AE, Guina T, Tam VH, Louie A, Drusano GL, Hoover JL. Generating robust and informative nonclinical and bacterial infection model efficacy data to support translation to humans. Antimicrobial Agents and Chemotherapy. PMID 30833428 DOI: 10.1128/Aac.02307-18 |
0.324 |
|
| 2019 |
Rizk ML, Bhavnani SM, Drusano G, Dane A, Eakin AE, Guina T, Jang SH, Tomayko JF, Wang J, Zhuang L, Lodise TP. Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents. Antimicrobial Agents and Chemotherapy. PMID 30833427 DOI: 10.1128/Aac.02309-18 |
0.358 |
|
| 2019 |
Drusano GL, Louie A. Breakpoint determination when multiple organisms are tested for effect targets. European Journal of Pharmaceutical Sciences. 130: 196-199. PMID 30711687 DOI: 10.1016/J.Ejps.2019.01.033 |
0.363 |
|
| 2019 |
Foerster S, Drusano G, Golparian D, Neely M, Piddock L, Alirol E, Unemo M. O06.2 In vitro combination testing and selection of resistance to zoliflodacin combined with six antimicrobials for N. gonorrhoeae Sexually Transmitted Infections. 95. DOI: 10.1136/Sextrans-2019-Sti.135 |
0.444 |
|
| 2018 |
de Miranda Silva C, Hajihosseini A, Myrick J, Nole J, Louie A, Schmidt S, Drusano GL. Effect of Moxifloxacin plus Pretomanid against in Log-phase, Acid-phase and Non-Replicating-Persister (NRP)-phase in an i Assay. Antimicrobial Agents and Chemotherapy. PMID 30397058 DOI: 10.1128/Aac.01695-18 |
0.311 |
|
| 2018 |
Heinrichs MT, Drusano GL, Brown DL, Maynard MS, Sy SKB, Rand KH, Peloquin CA, Louie A, Derendorf H. Dose Optimization of Moxifloxacin and Linezolid Against Tuberculosis Using Mathematical Modeling and Simulation. International Journal of Antimicrobial Agents. PMID 30385322 DOI: 10.1016/J.Ijantimicag.2018.10.012 |
0.378 |
|
| 2018 |
Drusano GL, Neely MN, Yamada WM, Duncanson B, Brown D, Maynard M, Vicchiarelli M, Louie A. The combination of fosfomycin plus meropenem is synergistic for PA01 in a Hollow Fiber Infection Model (HFIM). Antimicrobial Agents and Chemotherapy. PMID 30249700 DOI: 10.1128/Aac.01682-18 |
0.468 |
|
| 2018 |
Louie A, Duncanson B, Myrick J, Maynard M, Nole J, Brown D, Schmidt S, Neely M, Scanga CA, Peloquin C, Drusano GL. The Activity of Moxifloxacin against Acid-Phase and Non-Replicative Persister Phenotype Phase in a Hollow Fiber Infection Model. Antimicrobial Agents and Chemotherapy. PMID 30249693 DOI: 10.1128/Aac.01470-18 |
0.414 |
|
| 2018 |
Pires de Mello CP, Drusano GL, Rodriquez JL, Kaushik A, Brown AN. Antiviral Effects of Clinically-Relevant Interferon-α and Ribavirin Regimens against Dengue Virus in the Hollow Fiber Infection Model (HFIM). Viruses. 10. PMID 29890736 DOI: 10.3390/V10060317 |
0.375 |
|
| 2018 |
de Miranda Silva C, Hajihosseini A, Myrick J, Nole J, Louie A, Schmidt S, Drusano GL. Effect of Linezolid plus Bedaquiline against in Log-Phase, Acid-Phase and Non-Replicating-Persister (NRP)-Phase in an Assay. Antimicrobial Agents and Chemotherapy. PMID 29866874 DOI: 10.1128/Aac.00856-18 |
0.388 |
|
| 2018 |
Drusano GL, Myrick J, Maynard M, Nole J, Duncanson B, Brown D, Schmidt S, Neely M, Scanga CA, Peloquin C, Louie A. Linezolid Kills Acid Phase and Non-replicative Persister Phase in a Hollow Fiber Infection Model. Antimicrobial Agents and Chemotherapy. PMID 29866864 DOI: 10.1128/Aac.00221-18 |
0.354 |
|
| 2018 |
Louie A, Maynard M, Duncanson B, Nole J, Vicchiarelli M, Drusano GL. Determination of the dynamically-linked indices of fosfomycin forin the Hollow Fiber Infection Model (HFIM). Antimicrobial Agents and Chemotherapy. PMID 29581114 DOI: 10.1128/Aac.02627-17 |
0.51 |
|
| 2018 |
Papp-Wallace KM, Zeiser ET, Becka SA, Park ST, Winkler ML, Nguyen K, Singh I, Sutton G, Fouts DE, Ellis-Grosse EJ, Drusano GL, Perlin DS, Bonomo RA. 2385. Ceftazidime–Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa Open Forum Infectious Diseases. 5. DOI: 10.1093/Ofid/Ofy210.2038 |
0.406 |
|
| 2017 |
Brown AN, Liu L, Rodriquez JL, Zhao L, Schuster L, Li E, Wang GP, Neely MN, Yamada W, Drusano GL. Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV). Scientific Reports. 7: 14421. PMID 29089577 DOI: 10.1038/S41598-017-15007-2 |
0.436 |
|
| 2017 |
Pires de Mello CP, Drusano GL, Adams JR, Shudt M, Kulawy R, Brown AN. Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system. European Journal of Pharmaceutical Sciences : Official Journal of the European Federation For Pharmaceutical Sciences. PMID 29079337 DOI: 10.1016/J.Ejps.2017.10.027 |
0.397 |
|
| 2017 |
Drusano GL, Corrado ML, Girardi G, Ellis-Grosse EJ, Wunderink RG, Donnelly H, Leeper KV, Brown M, Malek T, Hite RD, Ferrari M, Djureinovic D, Kollef MH, Mayfield L, Doyle A, et al. Dilution Factor of Quantitative Bacterial Cultures Obtained by Bronchoalveolar Lavage in Patients with Ventilator-Associated Bacterial Pneumonia: Implications for Optimal Antimicrobial Therapy Ventilator-Associated Bacterial Pneumonia Study Group. Antimicrobial Agents and Chemotherapy. PMID 29038277 DOI: 10.1128/Aac.01323-17 |
0.434 |
|
| 2017 |
Drusano GL. Pre-clinical in vitro infection models. Current Opinion in Pharmacology. 36: 100-106. PMID 29035729 DOI: 10.1016/J.Coph.2017.09.011 |
0.457 |
|
| 2017 |
Heine HS, Shadomy SV, Boyer AE, Chuvala L, Riggins R, Kesterson A, Myrick J, Craig J, Candela MG, Barr JR, Hendricks K, Bower WA, Walke H, Drusano GL. Evaluation of Combination Drug Therapy for Treatment of Antibiotic Resistant Inhalation Anthrax in a Murine Model. Antimicrobial Agents and Chemotherapy. PMID 28696235 DOI: 10.1128/Aac.00788-17 |
0.411 |
|
| 2017 |
Drusano GL. Stepping Off the Resistance Treadmill. The Journal of Infectious Diseases. PMID 28475769 DOI: 10.1093/Infdis/Jix212 |
0.355 |
|
| 2017 |
Louie A, Maynard M, Duncanson B, Vicchiarelli M, Drusano GL. Fosfomycin (FOS) Plus Meropenem (MER) Suppresses Resistance Emergence Against P. aeruginosa (PA) PAO1 in the Hollow Fiber Infection Model (HFIM) Open Forum Infectious Diseases. 4. DOI: 10.1093/Ofid/Ofx163.1219 |
0.372 |
|
| 2016 |
Drusano GL. From lead optimization to NDA approval for a new antimicrobial: Use of pre-clinical effect models and pharmacokinetic/pharmacodynamic mathematical modeling. Bioorganic & Medicinal Chemistry. 24: 6401-6408. PMID 27612961 DOI: 10.1016/J.Bmc.2016.08.034 |
0.432 |
|
| 2016 |
Hope W, Drusano GL, Rex JH. Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality. The Journal of Antimicrobial Chemotherapy. PMID 27494925 DOI: 10.1093/Jac/Dkw298 |
0.359 |
|
| 2016 |
Heine HS, Chuvala L, Riggins R, Cirz R, Cass R, Louie A, Drusano GL. Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice. Antimicrobial Agents and Chemotherapy. 60: 1834-40. PMID 26824958 DOI: 10.1128/Aac.02887-15 |
0.387 |
|
| 2015 |
Drusano GL, Hope W, MacGowan A, Louie A. Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2. Antimicrobial Agents and Chemotherapy. 60: 1194-201. PMID 26711766 DOI: 10.1128/Aac.02231-15 |
0.456 |
|
| 2015 |
Drusano GL, Louie A, MacGowan A, Hope W. Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1. Antimicrobial Agents and Chemotherapy. 60: 1183-93. PMID 26711759 DOI: 10.1128/Aac.02177-15 |
0.457 |
|
| 2015 |
Bhavnani SM, Ambrose PG, Hammel JP, Rubino CM, Drusano GL. Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints to Support Risk versus Benefit Considerations. Antimicrobial Agents and Chemotherapy. PMID 26711755 DOI: 10.1128/Aac.02967-15 |
0.449 |
|
| 2015 |
Brown AN, Drusano GL, Adams JR, Rodriquez JL, Jambunathan K, Baluya DL, Brown DL, Kwara A, Mirsalis JC, Hafner R, Louie A. Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy. Mbio. 6. PMID 26530386 DOI: 10.1128/Mbio.01741-15 |
0.449 |
|
| 2015 |
Docobo-Pérez F, Drusano GL, Johnson A, Goodwin J, Whalley S, Ramos-Martín V, Ballestero-Tellez M, Rodriguez-Martinez JM, Conejo C, van Guilder M, Rodríguez-Baño J, Pascual A, Hope WW. Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance. Antimicrobial Agents and Chemotherapy. PMID 26124169 DOI: 10.1128/Aac.00752-15 |
0.494 |
|
| 2015 |
Brown AN, Adams JR, Baluya DL, Drusano GL. Pharmacokinetic Determinants of Virological Response to Raltegravir in the In Vitro Pharmacodynamic Hollow-Fiber Infection Model System. Antimicrobial Agents and Chemotherapy. 59: 3771-7. PMID 25870053 DOI: 10.1128/Aac.00469-15 |
0.422 |
|
| 2015 |
Louie A, Boyne MT, Patel V, Huntley C, Liu W, Fikes S, Kurhanewicz S, Rodriquez J, Robbins N, Brown D, Baluya D, Drusano GL. Pharmacodynamic evaluation of the activities of six parenteral vancomycin products available in the United States. Antimicrobial Agents and Chemotherapy. 59: 622-32. PMID 25385113 DOI: 10.1128/Aac.03710-14 |
0.39 |
|
| 2015 |
Bhavnani SM, Hammel JP, Van Wart SA, Rubino CM, Reynolds DK, Forrest A, Drusano GL, Khariton T, Friedland HD, Riccobene TA, Ambrose PG. Pharmacokinetic-pharmacodynamic analysis for efficacy of ceftaroline fosamil in patients with acute bacterial skin and skin structure infections. Antimicrobial Agents and Chemotherapy. 59: 372-80. PMID 25367904 DOI: 10.1128/Aac.02531-14 |
0.437 |
|
| 2015 |
Louie A, Liu W, VanGuilder M, Neely MN, Schumitzky A, Jelliffe R, Fikes S, Kurhanewicz S, Robbins N, Brown D, Baluya D, Drusano GL. Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia. The Journal of Infectious Diseases. 211: 1326-33. PMID 25362196 DOI: 10.1093/Infdis/Jiu603 |
0.367 |
|
| 2014 |
Drusano GL, Neely M, Van Guilder M, Schumitzky A, Brown D, Fikes S, Peloquin C, Louie A. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. Plos One. 9: e101311. PMID 25003557 DOI: 10.1371/Journal.Pone.0101311 |
0.458 |
|
| 2014 |
Lodise TP, Drusano GL, Zasowski E, Dihmess A, Lazariu V, Cosler L, McNutt LA. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 59: 666-75. PMID 24867791 DOI: 10.1093/Cid/Ciu398 |
0.45 |
|
| 2014 |
Lodise TP, Drusano GL, Lazariu V, El-Fawal N, Evans A, Graffunder E, Stellrecht K, Mendes RE, Jones RN, Cosler L, McNutt LA. Quantifying the matrix of relationships between reduced vancomycin susceptibility phenotypes and outcomes among patients with MRSA bloodstream infections treated with vancomycin . The Journal of Antimicrobial Chemotherapy. 69: 2547-55. PMID 24840624 DOI: 10.1093/Jac/Dku135 |
0.365 |
|
| 2014 |
Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. The Lancet. Infectious Diseases. 14: 498-509. PMID 24768475 DOI: 10.1016/S1473-3099(14)70036-2 |
0.463 |
|
| 2014 |
Drusano GL, Liu W, Fikes S, Cirz R, Robbins N, Kurhanewicz S, Rodriquez J, Brown D, Baluya D, Louie A. Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model. The Journal of Infectious Diseases. 210: 1319-24. PMID 24760199 DOI: 10.1093/Infdis/Jiu237 |
0.352 |
|
| 2014 |
Coleman K, Levasseur P, Girard AM, Borgonovi M, Miossec C, Merdjan H, Drusano G, Shlaes D, Nichols WW. Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrobial Agents and Chemotherapy. 58: 3366-72. PMID 24687507 DOI: 10.1128/Aac.00080-14 |
0.415 |
|
| 2014 |
Heine HS, Louie A, Adamovicz JJ, Amemiya K, Fast RL, Miller L, Opal SM, Palardy J, Parejo NA, Sörgel F, Kinzig-Schippers M, Drusano GL. Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. Antimicrobial Agents and Chemotherapy. 58: 3276-84. PMID 24687492 DOI: 10.1128/Aac.02420-14 |
0.359 |
|
| 2014 |
Lodise TP, Drusano GL. Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 58: S28-34. PMID 24343829 DOI: 10.1093/Cid/Cit615 |
0.47 |
|
| 2014 |
Perez F, Arias CA, Bush K, Drusano GL, Lolans K, Munoz-Price LS, Nicolau DP, Queenan AM, Rice LB, Segreti J, Shlaes DM, Weinstein RA, Bonomo RA. In memoriam: John P. Quinn, MD. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 58: 748-50. PMID 24336826 DOI: 10.1093/Cid/Cit801 |
0.415 |
|
| 2014 |
Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrobial Agents and Chemotherapy. 58: 309-16. PMID 24165176 DOI: 10.1128/Aac.01653-13 |
0.441 |
|
| 2013 |
Louie A, Vanscoy B, Liu W, Kulawy R, Drusano GL. Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children. Antimicrobial Agents and Chemotherapy. 57: 5946-60. PMID 24041894 DOI: 10.1128/Aac.02616-12 |
0.401 |
|
| 2013 |
Louie A, Liu W, Fikes S, Brown D, Drusano GL. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia. Antimicrobial Agents and Chemotherapy. 57: 2788-92. PMID 23571540 DOI: 10.1128/Aac.02624-12 |
0.498 |
|
| 2013 |
Heine HS, Chuvala L, Riggins R, Hurteau G, Cirz R, Cass R, Louie A, Drusano GL. Natural history of Yersinia pestis pneumonia in aerosol-challenged BALB/c mice. Antimicrobial Agents and Chemotherapy. 57: 2010-5. PMID 23403418 DOI: 10.1128/Aac.02504-12 |
0.309 |
|
| 2013 |
Drusano GL, Lodise TP. Saving lives with optimal antimicrobial chemotherapy. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 56: 245-7. PMID 23074312 DOI: 10.1093/Cid/Cis863 |
0.454 |
|
| 2012 |
Landersdorfer CB, Bulitta JB, Kirkpatrick CM, Kinzig M, Holzgrabe U, Drusano GL, Stephan U, Sörgel F. Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile. Antimicrobial Agents and Chemotherapy. 56: 5715-23. PMID 22908169 DOI: 10.1128/Aac.00937-12 |
0.408 |
|
| 2012 |
Felton TW, Hope WW, Lomaestro BM, Butterfield JM, Kwa AL, Drusano GL, Lodise TP. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. Antimicrobial Agents and Chemotherapy. 56: 4087-94. PMID 22585219 DOI: 10.1128/Aac.00521-12 |
0.418 |
|
| 2012 |
Balasubramanian V, Solapure S, Gaonkar S, Mahesh Kumar KN, Shandil RK, Deshpande A, Kumar N, Vishwas KG, Panduga V, Reddy J, Ganguly S, Louie A, Drusano GL. Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model. Antimicrobial Agents and Chemotherapy. 56: 3054-7. PMID 22470118 DOI: 10.1128/Aac.06383-11 |
0.388 |
|
| 2012 |
Ambrose PG, Drusano GL, Craig WA. In vivo activity of oritavancin in animal infection models and rationale for a new dosing regimen in humans. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 54: S220-8. PMID 22431852 DOI: 10.1093/Cid/Cis001 |
0.494 |
|
| 2012 |
Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrobial Agents and Chemotherapy. 56: 2795-805. PMID 22371890 DOI: 10.1128/Aac.05360-11 |
0.438 |
|
| 2012 |
Brown AN, McSharry JJ, Adams JR, Kulawy R, Barnard RJ, Newhard W, Corbin A, Hazuda DJ, Louie A, Drusano GL. Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system. Antimicrobial Agents and Chemotherapy. 56: 1170-81. PMID 22155837 DOI: 10.1128/Aac.05383-11 |
0.32 |
|
| 2012 |
Ambrose PG, Hammel JP, Bhavnani SM, Rubino CM, Ellis-Grosse EJ, Drusano GL. Frequentist and Bayesian pharmacometric-based approaches to facilitate critically needed new antibiotic development: overcoming lies, damn lies, and statistics. Antimicrobial Agents and Chemotherapy. 56: 1466-70. PMID 22155834 DOI: 10.1128/Aac.01743-10 |
0.333 |
|
| 2012 |
Louie A, VanScoy BD, Brown DL, Kulawy RW, Heine HS, Drusano GL. Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model. Antimicrobial Agents and Chemotherapy. 56: 1229-39. PMID 22155821 DOI: 10.1128/Aac.01109-10 |
0.377 |
|
| 2012 |
Nicasio AM, Bulitta JB, Lodise TP, D'Hondt RE, Kulawy R, Louie A, Drusano GL. Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model. Antimicrobial Agents and Chemotherapy. 56: 682-6. PMID 22083484 DOI: 10.1128/Aac.05664-11 |
0.488 |
|
| 2012 |
Cardone KE, Grabe DW, Kulawy RW, Daoui R, Roglieri J, Meola S, Drusano GL, Lodise TP. Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis. Antimicrobial Agents and Chemotherapy. 56: 725-30. PMID 22083473 DOI: 10.1128/Aac.05515-11 |
0.397 |
|
| 2012 |
Louie A, Vanscoy BD, Heine HS, Liu W, Abshire T, Holman K, Kulawy R, Brown DL, Drusano GL. Differential effects of linezolid and ciprofloxacin on toxin production by Bacillus anthracis in an in vitro pharmacodynamic system. Antimicrobial Agents and Chemotherapy. 56: 513-7. PMID 22064542 DOI: 10.1128/Aac.05724-11 |
0.339 |
|
| 2012 |
Louie A, Castanheira M, Liu W, Grasso C, Jones RN, Williams G, Critchley I, Thye D, Brown D, Vanscoy B, Kulawy R, Drusano GL. Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Antimicrobial Agents and Chemotherapy. 56: 258-70. PMID 22024819 DOI: 10.1128/Aac.05005-11 |
0.435 |
|
| 2012 |
Drusano GL, Bonomo RA, Bahniuk N, Bulitta JB, Vanscoy B, Defiglio H, Fikes S, Brown D, Drawz SM, Kulawy R, Louie A. Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 56: 231-42. PMID 22005996 DOI: 10.1128/Aac.05252-11 |
0.448 |
|
| 2011 |
Kees MG, Lodise TP, Drusano GL. Determination of meropenem penetration into the lung from Sparse data. Antimicrobial Agents and Chemotherapy. 55: 5959-61. PMID 22081725 DOI: 10.1128/Aac.05066-11 |
0.381 |
|
| 2011 |
Drusano GL, Liu W, Kulawy R, Louie A. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrobial Agents and Chemotherapy. 55: 5300-5. PMID 21911576 DOI: 10.1128/Aac.00502-11 |
0.465 |
|
| 2011 |
Lodise TP, Drusano GL, Butterfield JM, Scoville J, Gotfried M, Rodvold KA. Penetration of vancomycin into epithelial lining fluid in healthy volunteers. Antimicrobial Agents and Chemotherapy. 55: 5507-11. PMID 21911567 DOI: 10.1128/Aac.00712-11 |
0.38 |
|
| 2011 |
Drusano GL, Sgambati N, Eichas A, Brown D, Kulawy R, Louie A. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system. Mbio. 2: e00108-11. PMID 21750119 DOI: 10.1128/Mbio.00108-11 |
0.397 |
|
| 2011 |
Butterfield JM, Patel N, Pai MP, Rosano TG, Drusano GL, Lodise TP. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrobial Agents and Chemotherapy. 55: 4277-82. PMID 21670191 DOI: 10.1128/Aac.01674-10 |
0.301 |
|
| 2011 |
Drusano GL, Lodise TP, Melnick D, Liu W, Oliver A, Mena A, VanScoy B, Louie A. Meropenem penetration into epithelial lining fluid in mice and humans and delineation of exposure targets. Antimicrobial Agents and Chemotherapy. 55: 3406-12. PMID 21576431 DOI: 10.1128/Aac.01559-10 |
0.462 |
|
| 2011 |
Mortensen NP, Fowlkes JD, Maggart M, Doktycz MJ, Nataro JP, Drusano G, Allison DP. Effects of sub-minimum inhibitory concentrations of ciprofloxacin on enteroaggregative Escherichia coli and the role of the surface protein dispersin. International Journal of Antimicrobial Agents. 38: 27-34. PMID 21570813 DOI: 10.1016/J.Ijantimicag.2011.03.011 |
0.384 |
|
| 2011 |
McSharry JJ, Drusano GL. Antiviral pharmacodynamics in hollow fibre bioreactors. Antiviral Chemistry & Chemotherapy. 21: 183-92. PMID 21566264 DOI: 10.3851/Imp1770 |
0.342 |
|
| 2011 |
Louie A, Stein DS, Zack JZ, Liu W, Conde H, Fregeau C, Vanscoy BD, Drusano GL. Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin B-desoxycholate for treatment of murine systemic candidiasis. Antimicrobial Agents and Chemotherapy. 55: 3295-304. PMID 21502626 DOI: 10.1128/Aac.01324-10 |
0.355 |
|
| 2011 |
Louie A, Liu W, Kulawy R, Drusano GL. In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrobial Agents and Chemotherapy. 55: 3453-60. PMID 21502615 DOI: 10.1128/Aac.01565-10 |
0.496 |
|
| 2011 |
Louie A, Vanscoy B, Liu W, Kulawy R, Brown D, Heine HS, Drusano GL. Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy. 55: 2623-8. PMID 21486959 DOI: 10.1128/Aac.01374-10 |
0.485 |
|
| 2011 |
Drusano GL. What are the properties that make an antibiotic acceptable for therapy of community-acquired pneumonia? The Journal of Antimicrobial Chemotherapy. 66: iii61-7. PMID 21482571 DOI: 10.1093/Jac/Dkr100 |
0.442 |
|
| 2011 |
Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 52: 969-74. PMID 21460308 DOI: 10.1093/Cid/Cir078 |
0.405 |
|
| 2011 |
Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, MacGowan A, Theuretzbacher U, Turnidge J. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 14: 107-17. PMID 21440486 DOI: 10.1016/J.Drup.2011.02.005 |
0.454 |
|
| 2011 |
Drusano GL, VanScoy B, Liu W, Fikes S, Brown D, Louie A. Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia Antimicrobial Agents and Chemotherapy. 55: 2693-2695. PMID 21422203 DOI: 10.1128/Aac.01687-10 |
0.376 |
|
| 2011 |
Drusano GL, Louie A. Optimization of aminoglycoside therapy Antimicrobial Agents and Chemotherapy. 55: 2528-2531. PMID 21402835 DOI: 10.1128/Aac.01314-10 |
0.413 |
|
| 2011 |
Cardone KE, Lodise TP, Patel N, Hoy CD, Meola S, Manley HJ, Drusano GL, Grabe DW. Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis. Clinical Journal of the American Society of Nephrology : Cjasn. 6: 1081-8. PMID 21393490 DOI: 10.2215/Cjn.08510910 |
0.411 |
|
| 2011 |
Lodise TP, Sorgel F, Melnick D, Mason B, Kinzig M, Drusano GL. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia Antimicrobial Agents and Chemotherapy. 55: 1606-1610. PMID 21300830 DOI: 10.1128/Aac.01330-10 |
0.393 |
|
| 2011 |
Patel N, Cardone K, Grabe DW, Meola S, Hoy C, Manley H, Drusano GL, Lodise TP. Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis. Antimicrobial Agents and Chemotherapy. 55: 1677-83. PMID 21282429 DOI: 10.1128/Aac.01224-10 |
0.417 |
|
| 2011 |
Brown AN, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL. Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system. Antimicrobial Agents and Chemotherapy. 55: 1740-6. PMID 21263046 DOI: 10.1128/Aac.01628-10 |
0.375 |
|
| 2011 |
Brown AN, Bulitta JB, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL. Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model. Antimicrobial Agents and Chemotherapy. 55: 1747-53. PMID 21263045 DOI: 10.1128/Aac.01629-10 |
0.372 |
|
| 2011 |
Lodise TP, Drusano GL. Pharmacokinetics and pharmacodynamics: optimal antimicrobial therapy in the intensive care unit. Critical Care Clinics. 27: 1-18. PMID 21144983 DOI: 10.1016/J.Ccc.2010.11.003 |
0.421 |
|
| 2011 |
Louie A, Heine HS, VanScoy B, Eichas A, Files K, Fikes S, Brown DL, Liu W, Kinzig-Schippers M, Sörgel F, Drusano GL. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance Antimicrobial Agents and Chemotherapy. 55: 822-830. PMID 21115791 DOI: 10.1128/Aac.00818-10 |
0.532 |
|
| 2010 |
Drusano GL. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity. The Journal of Antimicrobial Chemotherapy. 65: iv33-9. PMID 21115453 DOI: 10.1093/Jac/Dkq253 |
0.467 |
|
| 2010 |
Drusano GL, Sgambati N, Eichas A, Brown DL, Kulawy R, Louie A. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. Mbio. 1. PMID 20802826 DOI: 10.1128/mBio.00139-10 |
0.353 |
|
| 2010 |
Ambrose PG, Bhavnani SM, Ellis-Grosse EJ, Drusano GL. Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 51: S103-10. PMID 20597657 DOI: 10.1086/653057 |
0.377 |
|
| 2010 |
Drusano GL, Fregeau C, Liu W, Brown DL, Louie A. Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model. Antimicrobial Agents and Chemotherapy. 54: 4368-72. PMID 20516275 DOI: 10.1128/Aac.00133-10 |
0.388 |
|
| 2010 |
Moriyama B, Henning SA, Childs R, Holland SM, Anderson VL, Morris JC, Wilson WH, Drusano GL, Walsh TJ. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. The Annals of Pharmacotherapy. 44: 929-35. PMID 20371747 DOI: 10.1345/Aph.1M717 |
0.44 |
|
| 2010 |
Louie A, Grasso C, Bahniuk N, Van Scoy B, Brown DL, Kulawy R, Drusano GL. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrobial Agents and Chemotherapy. 54: 2646-54. PMID 20368395 DOI: 10.1128/AAC.00065-10 |
0.373 |
|
| 2010 |
Louie A, Bied A, Fregeau C, Van Scoy B, Brown D, Liu W, Bush K, Queenan AM, Morrow B, Khashab M, Kahn JB, Nicholson S, Kulawy R, Drusano GL. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrobial Agents and Chemotherapy. 54: 2638-45. PMID 20308371 DOI: 10.1128/AAC.01721-09 |
0.358 |
|
| 2010 |
Bulitta J, Landersdorfer C, Huttner S, Drusano G, Kinzig M, Holzgrabe U, Stephan U, Sorgel F. Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers Antimicrobial Agents and Chemotherapy. 54: 1275-1282. PMID 20065059 DOI: 10.1128/Aac.00936-09 |
0.356 |
|
| 2010 |
Bhavnani SM, Rubino CM, Ambrose PG, Babinchak TJ, Korth-Bradley JM, Drusano GL. Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections Antimicrobial Agents and Chemotherapy. 54: 1207-1212. PMID 20038623 DOI: 10.1128/Aac.00182-09 |
0.379 |
|
| 2010 |
Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients Antimicrobial Agents and Chemotherapy. 54: 460-465. PMID 19858253 DOI: 10.1128/Aac.00296-09 |
0.312 |
|
| 2009 |
Bulitta JB, Duffull SB, Landersdorfer CB, Kinzig M, Holzgrabe U, Stephan U, Drusano GL, Sörgel F. Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers. Diagnostic Microbiology and Infectious Disease. 65: 130-41. PMID 19748423 DOI: 10.1016/J.Diagmicrobio.2009.06.018 |
0.363 |
|
| 2009 |
Drusano GL, Okusanya OO, Okusanya AO, Van Scoy B, Brown DL, Fregeau C, Kulawy R, Kinzig M, Sörgel F, Heine HS, Louie A. Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis Antimicrobial Agents and Chemotherapy. 53: 4718-4725. PMID 19687233 DOI: 10.1128/Aac.00802-09 |
0.415 |
|
| 2009 |
Hope WW, Drusano GL. Antifungal pharmacokinetics and pharmacodynamics: Bridging from the bench to bedside Clinical Microbiology and Infection. 15: 602-612. PMID 19673971 DOI: 10.1111/J.1469-0691.2009.02913.X |
0.396 |
|
| 2009 |
Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 49: 507-14. PMID 19586413 DOI: 10.1086/600884 |
0.304 |
|
| 2009 |
van den Anker JN, Pokorna P, Kinzig-Schippers M, Martinkova J, de Groot R, Drusano GL, Sorgel F. Meropenem pharmacokinetics in the newborn. Antimicrobial Agents and Chemotherapy. 53: 3871-9. PMID 19581463 DOI: 10.1128/AAC.00351-09 |
0.316 |
|
| 2009 |
Landersdorfer CB, Kirkpatrick CM, Kinzig M, Bulitta JB, Holzgrabe U, Drusano GL, Sörgel F. Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid. Antimicrobial Agents and Chemotherapy. 53: 3902-7. PMID 19564368 DOI: 10.1128/Aac.01200-08 |
0.332 |
|
| 2009 |
Rodvold KA, Nicolau DP, Lodise TP, Khashab M, Noel GJ, Kahn JB, Gotfried M, Murray SA, Nicholson S, Laohavaleeson S, Tessier PR, Drusano GL. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrobial Agents and Chemotherapy. 53: 3294-301. PMID 19451287 DOI: 10.1128/Aac.00144-09 |
0.353 |
|
| 2009 |
Louie A, Fregeau C, Liu W, Kulawy R, Drusano GL. Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. Antimicrobial Agents and Chemotherapy. 53: 3325-30. PMID 19364849 DOI: 10.1128/AAC.00006-09 |
0.387 |
|
| 2009 |
Drusano GL, Liu W, Fregeau C, Kulawy R, Louie A. Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrobial Agents and Chemotherapy. 53: 2266-73. PMID 19289521 DOI: 10.1128/Aac.01680-08 |
0.424 |
|
| 2009 |
Drusano GL, Liu W, Brown DL, Rice LB, Louie A. Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus Journal of Infectious Diseases. 199: 219-226. PMID 19049435 DOI: 10.1086/595739 |
0.468 |
|
| 2008 |
Scaglione F, Esposito S, Leone S, Lucini V, Pannacci M, Ma L, Drusano GL. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia European Respiratory Journal. 34: 394-400. PMID 19213786 DOI: 10.1183/09031936.00149508 |
0.335 |
|
| 2008 |
Drusano GL, Okusanya OO, Okusanya A, Van Scoy B, Brown DL, Kulawy R, Sörgel F, Heine HS, Louie A. Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis? Antimicrobial Agents and Chemotherapy. 52: 3973-9. PMID 18725437 DOI: 10.1128/Aac.00453-08 |
0.427 |
|
| 2008 |
Beauchemin CA, McSharry JJ, Drusano GL, Nguyen JT, Went GT, Ribeiro RM, Perelson AS. Modeling amantadine treatment of influenza A virus in vitro. Journal of Theoretical Biology. 254: 439-51. PMID 18653201 DOI: 10.1016/J.Jtbi.2008.05.031 |
0.35 |
|
| 2008 |
Bhavnani SM, Forrest A, Hammel JP, Drusano GL, Rubino CM, Ambrose PG. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia. Diagnostic Microbiology and Infectious Disease. 62: 99-101. PMID 18583085 DOI: 10.1016/J.Diagmicrobio.2008.04.008 |
0.336 |
|
| 2008 |
Louie A, Heine HS, Kim K, Brown DL, VanScoy B, Liu W, Kinzig-Schippers M, Sörgel F, Drusano GL. Use of an In Vitro Pharmacodynamic Model To Derive a Linezolid Regimen That Optimizes Bacterial Kill and Prevents Emergence of Resistance in Bacillus anthracis Antimicrobial Agents and Chemotherapy. 52: 2486-2496. PMID 18458134 DOI: 10.1128/Aac.01439-07 |
0.485 |
|
| 2008 |
Lodise TP, Gotfried M, Barriere S, Drusano GL. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrobial Agents and Chemotherapy. 52: 2300-4. PMID 18426898 DOI: 10.1128/Aac.01110-07 |
0.342 |
|
| 2008 |
Ambrose PG, Anon JB, Bhavnani SM, Okusanya OO, Jones RN, Paglia MR, Kahn J, Drusano GL. Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis. Diagnostic Microbiology and Infectious Disease. 61: 13-20. PMID 18313879 DOI: 10.1016/J.Diagmicrobio.2008.01.010 |
0.393 |
|
| 2008 |
Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrobial Agents and Chemotherapy. 52: 1330-6. PMID 18227177 DOI: 10.1128/Aac.01602-07 |
0.394 |
|
| 2008 |
Hope WW, Mickiene D, Petraitis V, Petraitiene R, Kelaher AM, Hughes JE, Cotton MP, Bacher J, Keirns JJ, Buell D, Heresi G, Benjamin DK, Groll AH, Drusano GL, Walsh TJ. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. The Journal of Infectious Diseases. 197: 163-71. PMID 18171300 DOI: 10.1086/524063 |
0.304 |
|
| 2008 |
Gumbo T, Hiemenz J, Ma L, Keirns JJ, Buell DN, Drusano GL. Population pharmacokinetics of micafungin in adult patients. Diagnostic Microbiology and Infectious Disease. 60: 329-31. PMID 18024052 DOI: 10.1016/J.Diagmicrobio.2007.09.018 |
0.35 |
|
| 2008 |
Lodise TP, Kinzig-Schippers M, Drusano GL, Loos U, Vogel F, Bulitta J, Hinder M, Sörgel F. Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid. Antimicrobial Agents and Chemotherapy. 52: 1945-51. PMID 17485507 DOI: 10.1128/Aac.00736-06 |
0.37 |
|
| 2007 |
Ambrose PG, Forrest A, Craig WA, Rubino CM, Bhavnani SM, Drusano GL, Heine HS. Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. Antimicrobial Agents and Chemotherapy. 51: 4351-5. PMID 17875992 DOI: 10.1128/AAC.00251-07 |
0.32 |
|
| 2007 |
Louie A, Brown DL, Liu W, Kulawy RW, Deziel MR, Drusano GL. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy. 51: 3988-4000. PMID 17846144 DOI: 10.1128/Aac.00391-07 |
0.483 |
|
| 2007 |
Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RN, Sörgel F. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: Results of population pharmacokinetic modelling and Monte Carlo simulation Journal of Antimicrobial Chemotherapy. 60: 1038-1044. PMID 17785282 DOI: 10.1093/Jac/Dkm325 |
0.309 |
|
| 2007 |
Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrobial Agents and Chemotherapy. 51: 3781-8. PMID 17724157 DOI: 10.1128/Aac.01533-06 |
0.421 |
|
| 2007 |
Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 45: 753-60. PMID 17712761 DOI: 10.1086/520991 |
0.462 |
|
| 2007 |
Heine HS, Louie A, Sorgel F, Bassett J, Miller L, Sullivan LJ, Kinzig-Schippers M, Drusano GL. Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. The Journal of Infectious Diseases. 196: 782-7. PMID 17674322 DOI: 10.1086/520547 |
0.365 |
|
| 2007 |
Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials Clinical Infectious Diseases. 45. PMID 17582578 DOI: 10.1086/518137 |
0.335 |
|
| 2007 |
Landersdorfer CB, Kirkpatrick CM, Kinzig-Schippers M, Bulitta JB, Holzgrabe U, Drusano GL, Sörgel F. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin. Antimicrobial Agents and Chemotherapy. 51: 3290-7. PMID 17576847 DOI: 10.1128/Aac.01410-06 |
0.439 |
|
| 2007 |
Louie A, Deziel MR, Liu W, Drusano GL. Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy. Antimicrobial Agents and Chemotherapy. 51: 2661-7. PMID 17517837 DOI: 10.1128/Aac.00073-07 |
0.507 |
|
| 2007 |
Lodise TP, Nau R, Kinzig M, Jones RN, Drusano GL, Sörgel F. Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae. Diagnostic Microbiology and Infectious Disease. 58: 445-52. PMID 17512154 DOI: 10.1016/J.Diagmicrobio.2007.03.015 |
0.384 |
|
| 2007 |
Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L, Leary R, Jones RN, Drusano GL. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. The Journal of Infectious Diseases. 195: 1818-27. PMID 17492598 DOI: 10.1086/518003 |
0.362 |
|
| 2007 |
Bulitta JB, Duffull SB, Kinzig-Schippers M, Holzgrabe U, Stephan U, Drusano GL, Sörgel F. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers Antimicrobial Agents and Chemotherapy. 51: 2497-2507. PMID 17485505 DOI: 10.1128/Aac.01477-06 |
0.403 |
|
| 2007 |
Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, Drusano GL. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrobial Agents and Chemotherapy. 51: 2329-36. PMID 17438043 DOI: 10.1128/Aac.00185-07 |
0.467 |
|
| 2007 |
Lodise TP, Pypstra R, Kahn JB, Murthy BP, Kimko HC, Bush K, Noel GJ, Drusano GL. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrobial Agents and Chemotherapy. 51: 2378-87. PMID 17387149 DOI: 10.1128/Aac.01181-06 |
0.346 |
|
| 2007 |
Hope WW, Kruhlak MJ, Lyman CA, Petraitiene R, Petraitis V, Francesconi A, Kasai M, Mickiene D, Sein T, Peter J, Kelaher AM, Hughes JE, Cotton MP, Cotten CJ, Bacher J, ... ... Drusano GL, et al. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. The Journal of Infectious Diseases. 195: 455-66. PMID 17205486 DOI: 10.1086/510535 |
0.344 |
|
| 2007 |
Gumbo T, Drusano GL, Liu W, Kulawy RW, Fregeau C, Hsu V, Louie A. Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. Antimicrobial Agents and Chemotherapy. 51: 968-74. PMID 17194830 DOI: 10.1128/Aac.01337-06 |
0.418 |
|
| 2007 |
Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 44: 79-86. PMID 17143821 DOI: 10.1086/510079 |
0.428 |
|
| 2007 |
Tam VH, Louie A, Deziel MR, Liu W, Drusano GL. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrobial Agents and Chemotherapy. 51: 744-7. PMID 17116679 DOI: 10.1128/AAC.00334-06 |
0.331 |
|
| 2007 |
Drusano GL. Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia European Respiratory Review. 16: 45-49. DOI: 10.1183/09059180.00010304 |
0.325 |
|
| 2006 |
Chen M, Ma L, Drusano GL, Bertino JS, Nafziger AN. Sex differences in CYP3A activity using intravenous and oral midazolam. Clinical Pharmacology and Therapeutics. 80: 531-8. PMID 17112809 DOI: 10.1016/J.Clpt.2006.08.014 |
0.337 |
|
| 2006 |
Kao LM, Bush K, Barnewall R, Estep J, Thalacker FW, Olson PH, Drusano GL, Minton N, Chien S, Hemeryck A, Kelley MF. Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Antimicrobial Agents and Chemotherapy. 50: 3535-42. PMID 17065619 DOI: 10.1128/Aac.00090-06 |
0.402 |
|
| 2006 |
Hope WW, Warn PA, Sharp A, Howard S, Kasai M, Louie A, Walsh TJ, Drusano GL, Denning DW. Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect. Antimicrobial Agents and Chemotherapy. 50: 3680-8. PMID 16954320 DOI: 10.1128/Aac.00369-06 |
0.463 |
|
| 2006 |
Gumbo T, Drusano GL, Liu W, Ma L, Deziel MR, Drusano MF, Louie A. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrobial Agents and Chemotherapy. 50: 3695-700. PMID 16954319 DOI: 10.1128/Aac.00507-06 |
0.406 |
|
| 2006 |
Sprandel KA, Drusano GL, Hecht DW, Rotschafer JC, Danziger LH, Rodvold KA. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Diagnostic Microbiology and Infectious Disease. 55: 303-9. PMID 16887471 DOI: 10.1016/J.Diagmicrobio.2006.06.013 |
0.402 |
|
| 2006 |
Chen M, Nafziger AN, Drusano GL, Ma L, Bertino JS. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults Antimicrobial Agents and Chemotherapy. 50: 1222-1227. PMID 16569832 DOI: 10.1128/Aac.50.4.1222-1227.2006 |
0.303 |
|
| 2006 |
Lodise TP, Rhoney DH, Tam VH, McKinnon PS, Drusano GL. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagnostic Microbiology and Infectious Disease. 54: 223-30. PMID 16423490 DOI: 10.1016/J.Diagmicrobio.2005.09.007 |
0.341 |
|
| 2006 |
Drusano GL, Louie A, Deziel M, Gumbo T. The crisis of resistance: Identifying drug exposures to suppress amplification of resistant mutant subpopulations Clinical Infectious Diseases. 42: 525-532. PMID 16421797 DOI: 10.1086/499046 |
0.47 |
|
| 2006 |
Jumbe NL, Louie A, Miller MH, Liu W, Deziel MR, Tam VH, Bachhawat R, Drusano GL. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy. 50: 310-7. PMID 16377702 DOI: 10.1128/Aac.50.1.310-317.2006 |
0.758 |
|
| 2005 |
Drusano GL. Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics. Pharmacotherapy. 25: 150S-158S. PMID 16305286 DOI: 10.1592/phco.2005.25.12part2.150S |
0.311 |
|
| 2005 |
Deziel MR, Heine H, Louie A, Kao M, Byrne WR, Basset J, Miller L, Bush K, Kelly M, Drusano GL. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrobial Agents and Chemotherapy. 49: 5099-106. PMID 16304178 DOI: 10.1128/Aac.49.12.5099-5106.2005 |
0.446 |
|
| 2005 |
Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrobial Agents and Chemotherapy. 49: 5058-68. PMID 16304173 DOI: 10.1128/Aac.49.12.5058-5068.2005 |
0.44 |
|
| 2005 |
Gumbo T, Louie A, Deziel MR, Drusano GL. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. Antimicrobial Agents and Chemotherapy. 49: 3178-81. PMID 16048921 DOI: 10.1128/Aac.49.8.3178-3181.2005 |
0.455 |
|
| 2005 |
Hope WW, Warn PA, Sharp A, Reed P, Keevil B, Louie A, Denning DW, Drusano GL. Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis. The Journal of Infectious Diseases. 192: 673-80. PMID 16028137 DOI: 10.1086/432069 |
0.392 |
|
| 2005 |
Tam VH, Louie A, Deziel MR, Liu W, Leary R, Drusano GL. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. The Journal of Infectious Diseases. 192: 420-8. PMID 15995955 DOI: 10.1086/430611 |
0.467 |
|
| 2005 |
Lodise TP, Preston S, Bhargava V, Bryskier A, Nusrat R, Chapel S, Rangaraju M, Drusano GL. Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens. Diagnostic Microbiology and Infectious Disease. 52: 45-52. PMID 15878442 DOI: 10.1016/J.Diagmicrobio.2004.12.005 |
0.323 |
|
| 2005 |
Krueger WA, Bulitta J, Kinzig-Schippers M, Landersdorfer C, Holzgrabe U, Naber KG, Drusano GL, Sörgel F. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrobial Agents and Chemotherapy. 49: 1881-9. PMID 15855510 DOI: 10.1128/Aac.49.5.1881-1889.2005 |
0.43 |
|
| 2005 |
Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation Antimicrobial Agents and Chemotherapy. 49: 461-463. PMID 15616337 DOI: 10.1128/Aac.49.1.461-463.2005 |
0.326 |
|
| 2004 |
Ball AP, Bartlett JG, Craig WA, Drusano GL, Felmingham D, Garau JA, Klugman KP, Low DE, Mandell LA, Rubinstein E, Tillotson GS. Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC. Journal of Chemotherapy (Florence, Italy). 16: 419-36. PMID 15565907 DOI: 10.1179/Joc.2004.16.5.419 |
0.307 |
|
| 2004 |
Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. The Journal of Infectious Diseases. 190: 1642-51. PMID 15478070 DOI: 10.1086/424849 |
0.39 |
|
| 2004 |
Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clinical Therapeutics. 26: 1187-98. PMID 15476901 DOI: 10.1016/S0149-2918(04)80001-8 |
0.457 |
|
| 2004 |
Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. The Journal of Infectious Diseases. 189: 1590-7. PMID 15116294 DOI: 10.1086/383320 |
0.46 |
|
| 2004 |
Masterton R, Drusano G, Paterson DL, Park G. Appropriate antimicrobial treatment in nosocomial infections-the clinical challenges. The Journal of Hospital Infection. 1-12. PMID 14623198 DOI: 10.1016/S0195-6701(03)00294-9 |
0.344 |
|
| 2003 |
Preston SL, Piliero PJ, Bilello JA, Stein DS, Symonds WT, Drusano GL. In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours. Antimicrobial Agents and Chemotherapy. 47: 3393-9. PMID 14576093 DOI: 10.1128/AAC.47.11.3393-3399.2003 |
0.309 |
|
| 2003 |
Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH, Bachhawat R, Freeman C, Kahn JB, Bush K, Dudley MN, Miller MH, Drusano GL. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. The Journal of Clinical Investigation. 112: 275-85. PMID 12865415 DOI: 10.1172/Jci16814 |
0.772 |
|
| 2003 |
Drusano GL. Prevention of resistance: A goal for dose selection for antimicrobial agents Clinical Infectious Diseases. 36. PMID 12516029 DOI: 10.1086/344653 |
0.356 |
|
| 2002 |
Drusano GL, Bilello PA, Symonds WT, Stein DS, McDowell J, Bye A, Bilello JA. Pharmacodynamics of abacavir in an in vitro hollow-fiber model system Antimicrobial Agents and Chemotherapy. 46: 464-470. PMID 11796359 DOI: 10.1128/AAC.46.2.464-470.2002 |
0.319 |
|
| 2001 |
Louie A, Kaw P, Liu W, Jumbe N, Miller MH, Drusano GL. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection Antimicrobial Agents and Chemotherapy. 45: 845-851. PMID 11181370 DOI: 10.1128/Aac.45.3.845-851.2001 |
0.755 |
|
| 2001 |
Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrobial Agents and Chemotherapy. 45: 13-22. PMID 11120938 DOI: 10.1128/Aac.45.1.13-22.2001 |
0.326 |
|
| 2001 |
Preston SL, Drusano GL. Telithromycin: A once-daily, broad-spectrum ketolide for treatment of various respiratory infections Formulary. 36: 101-110. |
0.32 |
|
| 2000 |
Drusano GL, Lode H, Edwards JR. Meropenem: Clinical response in relation to in vitro susceptibility Clinical Microbiology and Infection. 6: 185-194. PMID 11168106 DOI: 10.1046/j.1469-0691.2000.00062.x |
0.305 |
|
| 2000 |
Drusano GL, D'Argenio DZ, Preston SL, Barone C, Symonds W, Lafon S, Rogers M, Prince W, Bye A, Bilello JA. Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir Antimicrobial Agents and Chemotherapy. 44: 1655-1659. PMID 10817724 DOI: 10.1128/Aac.44.6.1655-1659.2000 |
0.315 |
|
| 2000 |
Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections Enfermedades Infecciosas Y Microbiologia. 20: 191-197. |
0.334 |
|
| 1999 |
Louie A, Banerjee P, Drusano GL, Shayegani M, Miller MH. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans Antimicrobial Agents and Chemotherapy. 43: 2841-2847. PMID 10582869 |
0.323 |
|
| 1999 |
Rybak MJ, Abate BJ, Kang SL, Ruffing MJ, Lerner SA, Drusano GL. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrobial Agents and Chemotherapy. 43: 1549-55. PMID 10390201 |
0.337 |
|
| 1999 |
Preston SL, Drusano GL. Gatifloxacin: A new fluoroquinolone for use in community-acquired pneumonia and other infections Formulary. 34: 1002-1015. |
0.356 |
|
| 1998 |
Drusano GL. Infection in the intensive care unit: β-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing Clinical Infectious Diseases. 27. PMID 9710679 |
0.324 |
|
| 1998 |
Louie A, Liu QF, Drusano GL, Liu W, Mayers M, Anaissie E, Miller MH. Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans Antimicrobial Agents and Chemotherapy. 42: 1512-1514. PMID 9624506 DOI: 10.1128/Aac.42.6.1512 |
0.407 |
|
| 1998 |
Louie A, Drusano GL, Banerjee P, Liu QF, Liu W, Kaw P, Shayegani M, Taber H, Miller MH. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrobial Agents and Chemotherapy. 42: 1105-9. PMID 9593135 DOI: 10.1128/AAC.42.5.1105 |
0.34 |
|
| 1996 |
Drusano GL, Prichard M, Bilello PA, Bilello JA. Modeling combinations of antiretroviral agents in vitro with integration of pharmacokinetics: Guidance in regimen choice for clinical trial evaluation Antimicrobial Agents and Chemotherapy. 40: 1143-1147. PMID 8723455 DOI: 10.1128/Aac.40.5.1143 |
0.304 |
|
| 1996 |
Bilello JA, Bilello PA, Kort JJ, Dudley MN, Leonard J, Drusano GL. Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro. Antimicrobial Agents and Chemotherapy. 39: 2523-7. PMID 8585738 DOI: 10.1128/Aac.39.11.2523 |
0.314 |
|
| 1995 |
Bilello JA, Bilello PA, Prichard M, Robins T, Drusano GL. Reduction of the in vitro activity of a77003, an inhibitor of human immunodeficiency virus protease, by human serum α1acid glycoprotein Journal of Infectious Diseases. 171: 546-551. PMID 7876599 DOI: 10.1093/Infdis/171.3.546 |
0.309 |
|
| 1994 |
Bilello JA, Bauer G, Dudley MN, Cole GA, Drusano GL. Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies Antimicrobial Agents and Chemotherapy. 38: 1386-1391. PMID 8092842 DOI: 10.1128/AAC.38.6.1386 |
0.316 |
|
| 1993 |
Standiford HC, Walsh TJ, Drusano GL, Tatem BA, Townsend RJ. Serum inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus in volunteers receiving novobiocin and rifampin alone and in combination Diagnostic Microbiology and Infectious Disease. 17: 135-142. PMID 8243034 DOI: 10.1016/0732-8893(93)90024-2 |
0.422 |
|
| 1993 |
Wilson WR, Gilbert DN, Bisno AL, Freedman LR, Smith C, Drusano G, Kaye D. Evaluation of new anti-infective drugs for the treatment of infective endocarditis. Infectious Diseases Society of America and the Food and Drug Administration. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. S89-95. PMID 1477254 DOI: 10.1093/Clind/15.Supplement_1.S89 |
0.38 |
|
| 1992 |
Drusano GL, Yuen GJ, Morse G, Cooley TP, Seidlin M, Lambert JS, Liebman HA, Valentine FT, Dolin R. Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials Antimicrobial Agents and Chemotherapy. 36: 1280-1283. PMID 1416828 DOI: 10.1128/AAC.36.6.1280 |
0.318 |
|
| 1990 |
Drusano GL. Human pharmacodynamics of beta-lactams, aminoglycosides and their combination Scandinavian Journal of Infectious Diseases, Supplement. 22: 235-248. PMID 2097712 |
0.327 |
|
| 1988 |
Drusano GL. Role of pharmacokinetics in the outcome of infections Antimicrobial Agents and Chemotherapy. 32: 289-297. PMID 3284456 |
0.315 |
|
| 1987 |
Standiford HC, Drusano GL, Forrest A, Tatem B, Plaisance K. Bactericidal activity of ciprofloxacin compared with that of cefotaxime in normal volunteers Antimicrobial Agents and Chemotherapy. 31: 1177-1182. PMID 3631942 DOI: 10.1128/Aac.31.8.1177 |
0.444 |
|
| 1986 |
Drusano GL, Townsend RJ, Walsh TJ, Forrest A, Antal EJ, Standiford HC. Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination. Antimicrobial Agents and Chemotherapy. 30: 42-5. PMID 3752982 DOI: 10.1128/AAC.30.1.42 |
0.397 |
|
| 1986 |
Standiford HC, Drusano GL, Bustamante CI, Rivera G, Forrest A, Tatem B, Leslie J, Moody M. Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. Antimicrobial Agents and Chemotherapy. 29: 412-417. PMID 3459390 DOI: 10.1128/Aac.29.3.412 |
0.444 |
|
| 1986 |
Gonzalez MA, Moranchel AH, Duran S, Pichardo A, Magana JL, Painter B, Forrest A, Drusano GL. Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrobial Agents and Chemotherapy. 28: 235-9. PMID 2939794 DOI: 10.1128/AAC.28.2.235 |
0.311 |
|
| 1985 |
Wade JC, Standiford HC, Drusano GL, Johnson DE, Moody MR, Bustamante CI, Joshi JH, deJongh C, Schimpff SC. Potential of imipenem as single-agent empiric antibiotic therapy of febrile neutropenic patients with cancer. The American Journal of Medicine. 78: 62-72. PMID 3859217 DOI: 10.1016/0002-9343(85)90103-2 |
0.309 |
|
| 1985 |
Drusano GL, Standiford HC. Pharmacokinetic profile of lmipenem/cilastatin in normal volunteers The American Journal of Medicine. 78: 47-53. PMID 3859215 DOI: 10.1016/0002-9343(85)90101-9 |
0.319 |
|
| 1984 |
Herrington D, Drusano GL, Smalls U, Standiford HC. False Elevation in Serum Creatinine Levels Jama: the Journal of the American Medical Association. 252: 2962. PMID 6502857 DOI: 10.1001/Jama.1984.03350210018019 |
0.347 |
|
| 1984 |
Bustamante CI, Drusano GL, Tatem BA, Standiford HC. Postantibiotic effect of imipenem on Pseudomonas aeruginosa Antimicrobial Agents and Chemotherapy. 26: 678-682. PMID 6440477 DOI: 10.1128/Aac.26.5.678 |
0.344 |
|
| 1984 |
Standiford HC, Drusano GL, Fitzpatrick B, Tatem B, Schimpff SC. Bactericidal activity of ceftazidime serum compared with that of ticarcillin combined with amikacin Antimicrobial Agents and Chemotherapy. 26: 339-342. PMID 6439114 DOI: 10.1128/Aac.26.3.339 |
0.396 |
|
| 1984 |
Drusano GL, Standiford HC, Fitzpatrick B, Leslie J, Tangtatsawasdi P, Ryan P, Tatem B, Moody MR, Schimpff SC. Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers. Antimicrobial Agents and Chemotherapy. 26: 388-393. PMID 6391372 DOI: 10.1128/Aac.26.3.388 |
0.427 |
|
| 1984 |
Drusano GL, Schimpff SC, Hewitt WL. The acylampicillins: mezlocillin, piperacillin, and azlocillin Reviews of Infectious Diseases. 6: 13-32. PMID 6369480 |
0.338 |
|
| 1984 |
Drusano GL, Ryan PA, Standiford HC, Moody MR, Schimpff SC. Integration of selected pharmacologic and microbiologic properties of three new beta-lactam antibiotics: a hypothesis for rational comparison Reviews of Infectious Diseases. 6: 357-363. PMID 6330835 |
0.325 |
|
| 1982 |
Standiford HC, Drusano GL, McNamee WB, Tatem B, Ryan PA, Schimpff SC. Comparative pharmacokinetics of moxalactam, cefoperazone, and cefotaxime in normal volunteers Reviews of Infectious Diseases. 4. PMID 6296967 DOI: 10.1093/Clinids/4.Supplement_3.S585 |
0.358 |
|
| 1981 |
Saah AJ, Drusano GL, Warren JW, Tenney JH, Caplan ES. Cefoxitin-resistant facultative or aerobic gram-negative bacilli in infections associated with the gastrointestinal tract Annals of Internal Medicine. 94: 487-488. PMID 7212506 |
0.3 |
|
| Show low-probability matches. |